EUVIMEDObjevte EUVIMED
Crossref

PDZ‐binding kinase aggravates pancreatic neuroendocrine neoplasm progression by activating the AKT/mTOR pathway

Tingting Feng, Ruibin Jiang, Lu Yin, Chenyang Xu, Jian Ma, Wenjuan Yin, Jiaoyue Jin, Tingting Lu, Xinyuan Liu, Yingqi Lyu, Ying Yang, Lisha Ying and 3 more

Molecular Carcinogenesis · 2023

DOI: 10.1002/mc.23519 ↗

At a glance

Journal article in Molecular Carcinogenesis, 2023. Written by Tingting Feng and 14 co-authors. Institution: Department of Pathology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine…. Major MEDLINE topics: Mitogen-Activated Protein Kinase Kinases, Neuroendocrine Tumors, Pancreatic Neoplasms. Cited 2 times so far (Crossref); 31 references. Funded by: Zhejiang Provincial Program for the Cultivation of High-Level Innovative Health Talents, Natural Science Foundation of Zhejiang Province.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

The therapeutic effects of existing drug regimens against pancreatic neuroendocrine neoplasms (pNENs) remain limited, and identifying ideal therapeutic targets is warranted. PDZ binding kinase (PBK) may play an oncogenic role in most solid tumors. However, its function in pNEN remains unclear. In this study, pNEN samples and International Cancer Genome Consortium data were used to determine the clinical significance of PBK. Cell counting and CCK8 assays were used to assess cell proliferation. Flow cytometry was used to assess drug‐induced apoptosis and cell cycle arrest. An in vivo PBK‐targeting experiment was performed in mice bearing pNENs. Western blotting, quantitative PCR, and immunohistochemistry were performed to assess the molecular mechanisms. PBK was significantly upregulated in pNEN tissues compared with paracancerous tissues. Additionally, PBK was a poor prognostic factor for pNEN patients. PBK was found to promote the proliferation of pNEN cells by activating the AKT/mTOR pathway. Furthermore, PBK inhibition combined with everolimus treatment had enhanced antitumour effects on pNEN via inhibiting AKT/mTOR pathway and inducing G0/G1 phase cell cycle arrest. This study highlights that PBK plays an oncogenic role in and is a promising therapeutic target for pNEN.

Subjects

MeSH terms (MEDLINE)

Mitogen-Activated Protein Kinase KinasesNeuroendocrine TumorsPancreatic NeoplasmsAnimalsMiceCell Line, TumorExtracellular Signal-Regulated MAP KinasesProto-Oncogene Proteins c-aktTOR Serine-Threonine Kinases

Author keywords

PDZ-binding kinaseeverolimusmTORpancreatic neuroendocrine neoplasmsproliferation

Substances

Extracellular Signal-Regulated MAP KinasesMitogen-Activated Protein Kinase KinasesPDZ-binding kinaseProto-Oncogene Proteins c-aktTOR Serine-Threonine Kinases

Authors and institutions

  • Department of Pathology, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang, C…
  • Cancer Research Institute, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Chinese Academy of Sciences, Hangzhou, Zhejiang,…
  • Department of Hepatobiliary and Pancreatic Surgery, The Center for Integrated Oncology and Precision Medicine, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, Chi…
  • Department of Oncology, The First Clinical Medical College of Wenzhou Medical University, Wenzhou, Zhejiang, China.
  • Department of Immunology, Harbin Medical University, Harbin, Heilongjiang, China.
  • The Second Clinical Medical College, Zhejiang University of Traditional Chinese Medicine, Hangzhou, China.

ORCID profiles: Sunbin Ling

Funding

  • Zhejiang Provincial Program for the Cultivation of High-Level Innovative Health Talents
  • Natural Science Foundation of Zhejiang Province

Cite

APA

Feng, T., Jiang, R., Yin, L., Xu, C., Ma, J., Yin, W., Jin, J., Lu, T., Liu, X., Lyu, Y., Yang, Y., Ying, L., Hu, Q., Su, D., & Ling, S. (2023). PDZ‐binding kinase aggravates pancreatic neuroendocrine neoplasm progression by activating the AKT/mTOR pathway. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23519

Vancouver

Feng T, Jiang R, Yin L, Xu C, Ma J, Yin W, et al. PDZ‐binding kinase aggravates pancreatic neuroendocrine neoplasm progression by activating the AKT/mTOR pathway. Molecular Carcinogenesis. 2023. doi:10.1002/mc.23519

BibTeX
@article{Feng2023,
  author = {Feng, Tingting and Jiang, Ruibin and Yin, Lu and Xu, Chenyang and Ma, Jian and Yin, Wenjuan and Jin, Jiaoyue and Lu, Tingting and Liu, Xinyuan and Lyu, Yingqi and Yang, Ying and Ying, Lisha and Hu, Qichao and Su, Dan and Ling, Sunbin},
  title = {PDZ‐binding kinase aggravates pancreatic neuroendocrine neoplasm progression by activating the AKT/mTOR pathway},
  journal = {Molecular Carcinogenesis},
  year = {2023},
  doi = {10.1002/mc.23519}
}
Start for free →